Chelation Therapy (for Nebraska Only)

Coverage Summary

This UnitedHealthcare medical policy applies only to Nebraska (State-specific). Policy number: CS016NE.O. Effective date: August 1, 2025.

Core stance: Chelation therapy is considered proven and medically necessary for documented heavy metal toxicity/overload (examples: iron, copper, lead, aluminum) when diagnosed using validated testing and appropriate biological samples; chelation is considered unproven and not medically necessary for treatment of chronic, progressive non-overload conditions (e.g., cardiovascular disease, neurodegenerative diseases, autism) and for mercury 'toxicity' from dental amalgam fillings.

Medical-Necessity Criteria

Medically Necessary Indications

Covered when ALL of the following are met:

Condition is heavy metal toxicity or overload (e.g., iron, copper, lead, aluminum) that has been accurately diagnosed
Diagnostic workup includes consideration of individual history, appropriate testing methods, and use of accurate and specific reference values
Chelating agent, route, method, and site of administration are appropriate to the agent used, toxicity level, and other clinical indications

Not Medically Necessary / Unproven Indications

Chelation therapy is considered unproven and not medically necessary when ANY of the following apply:

Chelation therapy for treating any chronic, progressive diseases associated with non-overload conditions (examples: cardiovascular disease, rheumatoid arthritis, cancer, diabetes, Alzheimer's disease, autism spectrum disorder, Parkinson's disease, and others)
Chelation therapy for treating mercury 'toxicity' from dental amalgam fillings
Use of chelation without validated testing in appropriate biological samples documenting metal intoxication
Chelation based on 'chelation challenge' urinary analyses (AAP recommends against for children with suspected lead poisoning)

Coverage Rationale (context from revision history)

Policy changes described in history indicate wording adjustments but no change to coverage guidelines:

Chelation therapy is considered proven and medically necessary for documented metal toxicity/overload conditions (e.g., iron, copper, lead, aluminum) when diagnosed using validated tests and appropriate biological samples and when therapy aligns with FDA-approved indications and general drug compendia.
Chelation therapy for non-overload conditions (for example autism, cardiovascular disease prevention/treatment, neurodegenerative conditions) is not supported by evidence for improving objective outcomes and is not recommended by multiple professional organizations.

Professional Guideline Recommendations & FDA Statements

Professional Guideline Recommendations (summarized)

Coverage guidance is informed by the following organizational positions:

American Academy of Pediatrics (AAP): Recommends against ordering 'chelation challenge' urinary analyses for children with suspected lead poisoning; states chelation challenge has no clinical utility (Mackara, 2021).
ACC/AHA and affiliated groups: Notes EDTA is not approved by FDA for preventing or treating cardiovascular disease and finds the usefulness of chelation in cardiac disease highly questionable (Fihn et al., 2014).
American College of Medical Toxicology (ACMT): States chelation is not recommended except for documented metal intoxication diagnosed with validated tests; notes chelation does not improve outcomes in autism, CVD, or neurodegenerative conditions and highlights potential harms (position statements 2013/2015; reviewed 2021).

Evidence Summary

Lee et al. 2024 (systematic review): Iron-chelation therapy (ICT) compliance varied by agent (DFO 48.8–85.1%, DFP 87.2–92.2%, DFX 90–100%); most studies showed a significant negative correlation between compliance and serum ferritin and links between poor compliance and increased liver, cardiac, and endocrinologic morbidity.

TELESTO 2020 (Angelucci et al., randomized placebo-controlled trial): Deferasirox (DFX) prolonged event-free survival in low- to intermediate-1-risk MDS versus placebo but had higher adverse event rates (AEs reported in 97.3% DFX vs 90.8% placebo).

TACT / TACT2 (Lamas et al., 2013, 2022, 2024): Mixed results in cardiac populations — the original TACT suggested subgroup benefits (notably in diabetes and anterior MI subgroups in post hoc analyses), while the 2024 TACT2 (EDTA-based chelation) did not show reduction in overall cardiovascular events despite lowering blood lead levels.

Cochrane reviews and systematic reviews (Villarruz-Sulit et al. 2020; others): Insufficient evidence to determine effectiveness of EDTA chelation for ASCVD; pooled RCTs show no clear benefit on mortality or major cardiovascular outcomes and overall low-to-moderate certainty.

ACMT statement (American College of Medical Toxicology): Recommends chelation only for documented metal intoxication diagnosed with validated tests in appropriate biological samples and notes significant potential harms; does not support chelation for autism, CVD, or neurodegenerative conditions.

Codes and Billing References

Relevant HCPCS/J-codes and other procedure codes (reference list)mixed

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Provider Actions & Denial Risk

Documentation Required

Document diagnosis and diagnostic testing

Providers must document an accurate diagnosis of heavy metal toxicity or overload (for example iron, copper, lead, aluminum) using validated testing methods and appropriate biological samples, along with individual history and specific reference values, to justify chelation therapy. Diagnostic workup should consider the patient's history, choice of testing methods, and use of accurate and specific reference values. Chelation is an established treatment for removing metal toxins when these criteria are met.

Documentation Required

Limit chelation to documented metal overload/toxicity

Ensure chelation is limited to documented metal intoxication/overload diagnosed using validated tests on appropriate biological samples and that use aligns with FDA-approved indications and recognized drug compendia. FDA-approved chelating agents are indicated for metal poisoning and iron overload only; use should be consistent with those approvals and general drug compendia.

Definitions

Chelation therapy: Administration of molecules that bind and promote excretion of specific metal toxins from the body; agent, route, and regimen vary by toxicity and clinical indication.

Non-overload condition: Clinical situations in which acute or chronic heavy metal toxicity has not been demonstrated and where removal of metal ions is hypothesized but not proven to provide therapeutic benefit.

Chelation challenge: A urinary analysis performed after administration of a chelating agent intended to assess body burden (historically used for lead); considered to have no clinical utility and may be potentially dangerous in children (AAP recommends against its use).

Revision History

08/01/2025revised

Title changed; coverage rationale language adjusted. Detail: Supporting information and references were updated to reflect current literature; archived previous policy version CS016.N. Text: 'Replaced language indicating "chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary and not addressed in this policy" with "chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary"; supporting information, clinical evidence, and references updated; previous policy CS016.N archived.'

11/01/2025addedLatest

Administrative creation of state-specific version for Nebraska. Detail: Created state-specific policy version for the state of Nebraska with no change to coverage guidelines. Text: 'Policy Number CS016NE.O created for Nebraska; no changes to coverage guidelines.'